GlassScriptPhysician profile
Jill J Mckenzie
NPI 1154513661
$1,222.34
in general payments reported to CMS, 2019-2025
12 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.86 · 2020: $19.64 · 2021: $124 · 2022: $192 · 2023: $123 · 2024: $241 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.08 | 2019-2024 | |
| Genzyme Corporation | $206.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $201.02 | 2023-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $198.50 | 2021-2025 | |
| Leo Pharma INC. | $90.31 | 2024-2025 | Adbry |
| Incyte Corporation | $82.27 | 2022-2025 | Opzelura |
| Ucb, INC. | $80.08 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $40.23 | 2021-2022 | |
| Lilly USA, LLC | $36.78 | 2021-2022 | |
| Janssen Biotech, INC. | $27.55 | 2022-2023 | Stelara, Remicade, Simponi Aria |
| Biofrontera INC. | $24.62 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.